Skip to main content

Use of Docetaxel plus Androgen-Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Patients

9 stars
Joung
Jae Young
Center for Prostate Cancer
National Cancer Center
Goyang
Republic of Korea
Show all authors
Kwon
Whi-An
Center for Prostate Cancer
National Cancer Center
Goyang
Republic of Korea
Kim
Sung Han
Center for Prostate Cancer
Goyang
Goyang
Republic of Korea
Seo
Ho Kyung
Center for Prostate Cancer
National Cancer Center
Goyang
Republic of Korea
Chung
Jinsoo
Center for Prostate Cancer
National Cancer Center
Goyang
Republic of Korea
Lee
Kang Hyun
Center for Prostate Cancer
National Cancer Center
Goyang
Republic of Korea
Yoon
Min Young
Center for Prostate Cancer
National Cancer Center
Goyang
Republic of Korea
Choi
Se Young
Urology
Asan Medical Center
Seoul
Republic of Korea
Kim
Choung-Soo
Urology
Asan Medical Center
Seoul
Republic of Korea
Park
Myungchan
Department of Urology
Haeundae Paik Hospital
Busan
Republic of Korea
Park
Sang Hyun
Department of Urology
Haeundae Paik Hospital
Busan
Republic of Korea
Park
Sung-Woo
Urology
Pusan National University Yangsan Hospital
Yangsan
Republic of Korea
Kim
Taek Sang
Urology
Kosin Gospel Hospital
Busan
Republic of Korea

Tabs

Speciality: 
Urology
Keywords: 
Prostate cancer, Docetaxel, Hormone-sensitive prostate cancer, chemotherapy